NuCana plc - American Depositary Share (NCNA): Price and Financial Metrics


NuCana plc - American Depositary Share (NCNA): $1.51

0.05 (+3.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NCNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NCNA Stock Price Chart Interactive Chart >

Price chart for NCNA

NCNA Price/Volume Stats

Current price $1.51 52-week high $3.32
Prev. close $1.46 52-week low $0.52
Day low $1.47 Volume 70,333
Day high $1.54 Avg. volume 153,495
50-day MA $1.03 Dividend yield N/A
200-day MA $1.07 Market Cap 78.79M

NuCana plc - American Depositary Share (NCNA) Company Bio


NuCana plc develops anti-cancer medicines for ovarian, biliary, pancreatic, colorectal, haematology, oncology, and breast cancers. NuCana produces oncology medicines using a proprietary technology platform for cancer patients. The company was incorporated in 1997 and is based in Edinburgh, the United Kingdom.


NCNA Latest News Stream


Event/Time News Detail
Loading, please wait...

NCNA Latest Social Stream


Loading social stream, please wait...

View Full NCNA Social Stream

Latest NCNA News From Around the Web

Below are the latest news stories about NUCANA PLC that investors may wish to consider to help them evaluate NCNA as an investment opportunity.

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

EDINBURGH, United Kingdom, Jan. 23, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is

Yahoo | January 23, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

William White on InvestorPlace | January 12, 2023

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely (NASDAQ:NCNA)

NuCana’s market cap is not reflecting potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. See why I rate NCNA stock a strong buy.

Seeking Alpha | January 8, 2023

NuCana plc: NuCana Announces Receipt of NASDAQ Notice

EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC …

Finanz Nachrichten | January 6, 2023

NuCana Announces Receipt of NASDAQ Notice

EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated January 3, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450(a)(1). The Notification Letter h

Yahoo | January 6, 2023

Read More 'NCNA' Stories Here

NCNA Price Returns

1-mo 128.79%
3-mo 43.81%
6-mo -16.57%
1-year -47.02%
3-year -71.62%
5-year -93.77%
YTD 128.79%
2022 -72.27%
2021 -46.99%
2020 -26.39%
2019 -57.93%
2018 43.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6934 seconds.